Pay in 4 interest-free payments of $6.10 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Your doctor can determine if treatment for hair loss is needed
Key findings: CagriSema achieved up to 23% weight loss at 84 weeks Tirzepatide showed numerical superiority (~25.5%) The trial did not meet non-inferiority vs tirzepatide Clinical interpretation: Despite not meeting the primary endpoint, an important signal emerges: targeting multiple biological pathways remains a compelling strategy Why this matters: Reinforces obesity as a complex neuroendocrine disease Supports the concept that multi-hormonal approaches may better impact the defended weight set point Moves the field closer to precision, mechanism-based therapies Safety: Consistent with the GLP-1 class Mainly gastrointestinal adverse events, generally mild to moderate and transient Whats next: Ongoing development with higher-dose CagriSema Expansion of the REDEFINE program FDA decision expected by late 2026 Take-home message: The future of obesity treatment lies not in a single pathway, but in strategically combining mechanisms to sustainably shift weight biology
Pipeline Medications Multiple oral GLP 1 formulations beyond Rybelsus are in late stage clinical trials
Follow the steps above for medication vials, and rotate injection sites weekly, usually in the abdomen or thigh
